Tikvah Therapeutics Names Nathan Andrew Shapira, M.D., Ph.D. Executive Director of Clinical Research and Development and Deputy Chief Medical Officer
8/2/2007 9:37:45 AM
ATLANTA, Aug. 2, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today the appointment of Nathan Andrew Shapira, M.D., Ph.D. as Executive Director of Clinical Research and Development and Deputy Chief Medical Officer. Dr. Shapira will help to lead teams of researchers in the design, development, and execution of clinical development programs for Tikvah Therapeutics' neurological and psychiatric pharmaceutical products.
comments powered by